|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Gamma
Secretase
Gamma secretase is an unusual multi-protein complex that is
required to produce beta amyloid. We have played a critical
leadership role characterizing how gamma secretase may affect
Alzheimer’s disease pathology. Our finding that functional
gamma secretase inhibitors appear to reduce beta amyloid levels
in the brain, published in the Journal of Neurochemistry
in 2001, was an important step in this area of Alzheimer’s
disease research. We continue to progress our gamma secretase
discovery program with unique molecules that affect the activity
of gamma secretase in a substrate-specific manner.
In November 2008, we announced that the development program for
ELND006, a small molecule gamma secretase inhibitor, had
commenced with dosing in a Phase 1 clinical study, and other
back-ups are
in preclinical development.
In addition to our internal programs, we retain certain rights
to Eli Lilly’s LY450139 compound, which arose from
collaborative research between us and Lilly that began in 1988
and ended in 1998. In 2008, Lilly initiated Phase 3 trials for
LY450139 for mild to moderate Alzheimer’s disease.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Gamma
Secretase
Gamma secretase is an unusual multi-protein complex that is
thought to play a significant role in the formation of beta
amyloid. We have played a critical leadership role in the
increased awareness of how gamma secretase may affect
Alzheimer’s disease pathology. Our finding, published in
the Journal of Neurochemistry in 2001, that functional
gamma secretase inhibitors appear to reduce beta amyloid levels
in the brain, was an important step in this area of
Alzheimer’s disease research. We continue to progress our
gamma secretase discovery program.
In addition to internal programs, we retain certain rights to an
Eli Lilly and Company (Lilly) LY 450139 compound, which arose
from a collaborative research between the two companies that
began in 1988 and ended in 1998. In January 2008, Lilly
announced that it has commenced preparatory work for Phase 3
trials for LY 450139
Table of Contents
for mild to moderate AD patients, with estimated enrollment of
1,500 patients. Each patient’s participation is
expected to last approximately two years.
This excerpt taken from the ELN 20-F filed Feb 28, 2007. Gamma
Secretase
Gamma secretase is an unusual multi-protein complex that is
thought to play a significant role in the formation of beta
amyloid. We have played a critical leadership role in the
increased awareness of how gamma secretase may affect
Alzheimer’s disease pathology. Our finding, published in
2001, that functional gamma secretase inhibitors appear to
reduce beta amyloid levels in the brain, was an important step
in this area of Alzheimer’s disease research. We continued
to progress our gamma secretase discovery program in 2006.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. Gamma
Secretase
Gamma secretase is an unusual multi-protein complex that is
thought to play a significant role in the formation of beta
amyloid. We have played a critical leadership role in the
increased awareness of how gamma secretase may affect
Alzheimer’s disease pathology. Our finding, published in
2001, that functional gamma secretase inhibitors appear to
reduce beta amyloid levels in the brain, was an important step
in this area of Alzheimer’s disease research. Our gamma
secretase research is currently in the preclinical discovery
phase.
| EXCERPTS ON THIS PAGE:
|
| |||||||
